Loading patent…
AssigneeSanofi Pasteur Limited
InventorsTimothy ALEFANTIS, Mario BARRO, Anthony BYERS, Philip DAVIDSON, Maryann GIEL-MOLONEY, Philippe-Alexandre GILBERT, Harold KLEANTHOUS, Armaghan NAIK, Konstantin PUGACHEV, Saranya SRIDHAR, William WARREN, Konstantin ZELDOVICH
Estimating the term…
Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.
An immunogenic composition, comprising:
The immunogenic composition according to any of the preceding claims, wherein the molecular sequence is an amino acid sequence or a nucleic acid sequence.
The immunogenic composition according to any of the preceding claims, wherein the one or more machine learning influenza virus HA comprise a wild type influenza virus HA molecular sequence.
The immunogenic composition according to any of the preceding claims, wherein the one or more machine learning influenza virus HA comprise a non-wild type influenza virus HA molecular sequence.
The immunogenic composition according to any of the preceding claims, wherein the one or more machine learning influenza virus HA is a recombinant influenza virus HA.
The immunogenic composition according to any of the preceding claims, wherein the machine learning model is trained to predict a biological response.
The immunogenic composition according to any of the preceding claims, wherein the first influenza virus HA is an H1 HA from an H1N1 influenza virus strain and the second influenza virus HA is an H3 HA from an H3N2 influenza virus strain.
The immunogenic composition according to any of the preceding claims, wherein the composition further comprises an adjuvant.
The immunogenic composition according to any of the preceding claims, wherein each ribonucleic acid molecule comprises one or more modified nucleotides.
The immunogenic composition according to any of the preceding claims, wherein the composition is formulated for intramuscular injection.
The immunogenic composition according to any of the preceding claims, wherein the ribonucleic acid molecule is encapsulated in an LNP comprising a cationic lipid, a PEGylated lipid, a cholesterol-based lipid, and a helper lipid.
Dependencies are inferred from the claim text.